Kathrin Davari, Tristan Holland, Laura Prassmayer, Giulia Longinotti, Kenneth P Ganley, Lisa J Pechilis, Iulia Diaconu, Prashant R Nambiar, Michael S Magee, Dolores J Schendel, Daniel Sommermeyer, Christian Ellinger. Development of a CD8 co-receptor independent T-cell receptor specific for tumor-associated antigen MAGE-A4 for next generation T-cell-based immunotherapy. Journal for ImmunoTherapy of Cancer; 9(3); 25 March 2021; doi: 10.1136/jitc-2020-002035
T cell receptor (TCR)-modified T cells for adoptive T cell therapy
Gary Waanders, Silke Raffegerst, Petra Prinz-Schulz, Maja Buerdek. The T cell therapy field faces preclinical and translational R&D challenges as it targets more complex diseases. Cell & Gene Therapy Insights 2021; 7(1), 71–80; doi: 10.18609/cgti.2021.017
Anja Mösch1,2, Silke Raffegerst2, Manon Weis2, Dolores J. Schendel2 and Dmitrij Frishman1. Machine Learning for Cancer Immunotherapies Based on Epitope Recognition by T Cell Receptors. Frontiers in Genetics Review published: 19 November 2019 doi: 10.3389/fgene.2019.01141
1 Department of Bioinformatics, Wissenschaftszentrum Weihenstephan, Technische Universität München, Freising, Germany,
2 Medigene Immunotherapies GmbH, a subsidiary of Medigene AG, Planegg, Germany
Jaravine, V., Raffegerst, S., Schendel, DJ., Frishman, D. Assessment of cancer and virus antigens for cross-reactivity in human tissues Bioinformatics 2017 Jan 1;33(1):104-111. doi: 10.1093/bioinformatics/btw567.
Schlenker, R., Olguín-Contreras, L., Leisegang, M., Schnappinger, J., Disovic, A., Rühland, S., Nelson, P., Leonhardt, H., Harz, H., Wilde, S., Schendel, D. Uckert, W., Willimsky, G. and Noessner, E. Cancer Research, 2017. Chimeric PD-1:28 receptor upgrades low-avidity T cells and restores effector function of tumor-infiltrating lymphocytes for adoptive cell therapy
Haase, K., Raffegerst, S., Schendel, D., Frishman, D. Expitope: a web server for epitope expression. Bioinformatics. 2015 Jun 1;31(11):1854-6. doi: 10.1093/bioinformatics/btv068.
Obenaus, M., Leitão, C., Leisegang, M., Chen, X., Gavvovidis, I., van der Bruggen, P., Uckert, W., Schendel, D.J. and Blankenstein, T. 2015. Identification of human T-cell receptors with optimal affinity to cancer antigens using antigen-negative humanized mice. Nature Biotechnology 33, 402–407 (2015).
Schendel, D.J. and P.D. Greenberg. 2014. The ABC’s of T cell receptor gene therapy. In: Cancer Immunotherapy Meets Oncology (Britten, C.M., Kreiter, S., Diken, M., Rammensee, H.-G., Eds). Pp. 117-126. Springer International Publishing, Switzerland, Heidelberg, Dordrecht, London, New York, 25.05.2014.
Pinto, S., Sommermeyer, D., Michel, C., Wilde, S., Schendel, D, Uckert, W., Blankenstein T., Kyewski, B. 2014. Mis-initiation of MART-1 transcription in the thymus and biased TCR usage can explain the high frequency of peripheral MART-1 specific T cells. Eur J Immunol. 2014 May 20 [Epub ahead of print].
Schendel, D.J. and Frankenberger, B. 2013. Limitations for TCR gene therapy by MHC-restricted fratricide and TCR-mediated hematopoietic stem cell toxicity. Oncoimmunology. 2013 Jan 1; 2(1):e22410.
Morgan, R. A., Chinnasamy, N., Abate-Daga, D., Gross, A., Robbins, P. F., Zheng, Z., Dudley, M. E., Feldman, S. A., Yang, J. C., Sherry, R. M., Phan, G., Hughes, M. S., Kammula, U. S., Miller, A., Hessman, C., Stewart, A., Restifo, R., Quezado, M. M. (+ other members of Pathology staff), Nath, A., Wang, D., Bielekova, B., Wuest, S., Nirmala, A., (+ others, NIMH deep sequencing group), Schendel, D. J., Wilde, S., Mosetter, B., Laurencot, C. and Rosenberg, S. A. 2013. Cancer regression and neurologic toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother. 36(2):133-151.
Wilde, S. and D.J., Schendel. 2012. High-quality and high-avidity T cell clones specific for tumor-targeted antigens and how to find them. Oncoimmunology. 1(9):1643-1644.
Wilde, S., Sommermeyer, D., Leisegang, M., Frankenberger, B., Mosetter, B., Uckert, W. and D. J. Schendel. 2012. Human antitumor CD8+ T cells producing Th1-polycytokines show superior antigen sensitivity and tumor recognition. J Immunol. 189(2): 598-605.
Wilde, S., Geiger, C., Milosevic, S., Mosetter, B., Eichenlaub, S. and D.J. Schendel. 2012. Generation of allo-restricted peptide-specific T cells using RNA-pulsed dendritic cells: A three phase experimental procedure. Oncoimmunology. 1(2): 129-140.
Leisegang M., Wilde S., Spranger S., Milosevic S., Frankenberger B., Uckert W. and D.J. Schendel. 2010. MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors. J. Clin. Invest. 120 (11): 3869-3877.
Wilde, S., Sommermeyer, D., Frankenberger, B., Schiemann, M., Milosevic, S., Spranger, S., Pohla, H., Uckert, W., Busch, D.H. and D.J. Schendel. 2009. Dendritic cells pulsed with RNA encoding allogeneic MHC and antigen induce T cells with superior anti-tumor activity and higher TCR functional avidity. Blood 114(10): 2131-2139.
Becker, C., Pohla, H., Frankenberger, B., Schüler, T., Assenmacher, M., Schendel, D.J. and Blankenstein, T. 2001. Adoptive tumor therapy with T lymphocytes enriched through an IFN-γ capture assay. Nat Med.; 7 (10):1159–1162.
Dendritic cell vaccines
Bigalke I., Eckl J., Solum G., Hønnåshagen K., Skoge L., Fløisand Y., Josefsen D., Sæbøe-Larssen S., Geiger C., Schendel D., Kvalheim G. 2018. Immune Monitoring of Vaccine Quality and Persistence of Specific T Cell Responses in Five AML Patients Receiving Extended Dendritic Cell Vaccination Under Compassionate Use
Subklewe M., Geiger C., Lichtenegger F., Javorovic M., Kvalheim G., Schendel D.J., Bigalke I. 2014. New generation dendritic cell vaccine for immunotherapy of acute myeloid leukemia. Cancer Immunology. 10.1007/s00262-014-1600-5
Lichtenegger, F. S., Mueller, K., Otte, B., Beck, B., Hiddemann, W., Schendel, D. J. and M. Subklewe. 2012. CD86 and IL-12p70 are key players for T helper 1 polarization and natural killer cell activation by Toll-like receptor-induced dendritic cells. PLoS One. 7(9): e44266.
Spranger, S., Frankenberger, B. and D. J. Schendel. 2012. NOD/scid IL-2Rgnull mice: a pre-clinical model system to evaluate human dendritic cell-based vaccine strategies in vivo. J Transl. Med. 10(1): 30. [Epub ahead of print]
Frankenberger, B. and D.J. Schendel. 2012. Third generation dendritic cell vaccines for tumor immunotherapy. Eur. J. Cell Biol. 91(1): 53-58 [Epub 2011 Mar 25]
Beck, B., Dörfel, D., Lichtenegger, F.S., Geiger, C., Lindner, L., Merk, M., Schendel, D.J., and M. Subklewe. 2011. Effects of TLR agonists on maturation and function of 3-day dendritic cells from AML patients in complete remission. J. Transl. Med. 9:151 [Epub. Sep. 13]
Spranger, S., Javorovic, M., Bürdek, M., Wilde, S., Mosetter, B., Tippmer, S., Bigalke, I., Geiger, C., Schendel, D.J. and B. Frankenberger. 2010. Generation of T helper-1 polarizing dendritic cells using the Toll-like receptor 7/8 agonist CL075. J. Immunol. 185(1): 738-747.
Bürdek M., Spranger S., Wilde S., Frankenberger B., Schendel D.J. and C. Geiger. 2010 Three-day dendritic cells for vaccine development: Antigen uptake, processing and presentation. J. Transl. Med. 8:90.
Javorovic, M., Wilde, S., Zobywalski, A., Noessner, E., Lennerz, V., Wölfel, T., and D.J. Schendel. 2008. Inhibitory effect of RNA pool complexity on stimulatory capacity of RNA-pulsed dendritic cells. J. Immunother 31(1): 52-62.
Zobywalski, A., Javorovic, M., Frankenberger, B., Pohla, H., Kremmer, E., Bigalke, I. and D.J. Schendel. 2007. Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70. J. Transl Med. 5:18 (highly accessed).